We are live on ! Find out more
TE

Tema ETFs Portfolio holdings

AUM $3.09B
1-Year Est. Return 72.72%
This Fund
S&P 500
This Quarter Est. Return
-2.81%
1 Year Est. Return
+72.72%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$93.9M
Cap. Flow
+$112M
Cap. Flow %
33.58%
Top 10 Hldgs %
28.51%
Holding
174
New
26
Increased
81
Reduced
34
Closed
27

Top Buys

Rank Stock Value
1
TEX icon
Terex
TEX
+$6.33M
2
HRI icon
Herc Holdings
HRI
+$6.32M
3
TKR icon
Timken Company
TKR
+$4.82M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.37M
5
VMC icon
Vulcan Materials
VMC
+$4.35M

Top Sells

Rank Stock Value
1
PRIM icon
Primoris Services
PRIM
+$7.13M
2
FLR icon
Fluor
FLR
+$5.32M
3
FSS icon
Federal Signal
FSS
+$5.11M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.53M
5
ASND icon
Ascendis Pharma A/S
ASND
+$1.85M

Sector Composition

Rank Sector Weight
1 Industrials 43.38%
2 Healthcare 33.02%
3 Utilities 7.31%
4 Technology 5.91%
5 Financials 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
126
Biogen
BIIB
$29.6B
$342K 0.1%
2,501
– –
SDGR icon
127
Schrodinger
SDGR
$1.13B
$325K 0.1%
16,457
-18,331
-53% -$412K
INCY icon
128
Incyte
INCY
$23.1B
$305K 0.09%
5,042
-25,336
-83% -$1.77M
SYK icon
129
Stryker
SYK
$122B
$297K 0.09%
798
– –
CGEM icon
130
Cullinan Oncology
CGEM
$1.08B
$296K 0.09%
39,164
+10,731
+38% +$103K
ILMN icon
131
Illumina
ILMN
$28.1B
$279K 0.08%
3,513
-10,726
-75% -$1.16M
CPRX
132
DELISTED
Catalyst Pharmaceutical
CPRX
$275K 0.08%
11,352
– –
AXSM icon
133
Axsome Therapeutics
AXSM
$11.5B
$271K 0.08%
+2,327
New +$265K
ARVN icon
134
Arvinas
ARVN
$516M
$269K 0.08%
38,315
+26,480
+224% +$415K
SNDX icon
135
Syndax Pharmaceuticals
SNDX
$2B
$260K 0.08%
+21,169
New +$299K
RCKT icon
136
Rocket Pharmaceuticals
RCKT
$376M
$246K 0.07%
36,863
-54,122
-59% -$535K
RLAY icon
137
Relay Therapeutics
RLAY
$4.21B
$233K 0.07%
89,110
+24,455
+38% +$95.8K
ORIC icon
138
Oric Pharmaceuticals
ORIC
$1.08B
$228K 0.07%
40,934
-4,542
-10% -$39.7K
DNLI icon
139
Denali Therapeutics
DNLI
$3.67B
$206K 0.06%
+15,174
New +$291K
XENE icon
140
Xenon Pharmaceuticals
XENE
$6.47B
$205K 0.06%
6,111
– –
NTLA icon
141
Intellia Therapeutics
NTLA
$1.54B
$189K 0.06%
26,537
-121,630
-82% -$1.23M
ACAD icon
142
Acadia Pharmaceuticals
ACAD
$4.32B
$176K 0.05%
10,596
– –
AUTL
143
Autolus Therapeutics
AUTL
$373M
$171K 0.05%
+110,428
New +$224K
CELC icon
144
Celcuity
CELC
$4.35B
$158K 0.05%
+15,619
New +$177K
RCUS icon
145
Arcus Biosciences
RCUS
$3.57B
$120K 0.04%
15,251
-6,982
-31% -$80.9K
TALK icon
146
Talkspace
TALK
$873M
$71.3K 0.02%
27,834
+1,497
+6% +$4.66K
VYGR icon
147
Voyager Therapeutics
VYGR
$186M
$50.6K 0.02%
14,960
– –
AEIS icon
148
Advanced Energy
AEIS
$11.2B
– –
-3,528
Closed -$408K
AGIO icon
149
Agios Pharmaceuticals
AGIO
$2.39B
– –
-25,735
Closed -$846K
AGX icon
150
Argan
AGX
$8.38B
– –
-1,792
Closed -$246K
3 4 5
6
7

Similar funds

DCM
Donaldson Capital Management Evansville, Indiana $3.09B AUM 21.24% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
CAM
Contour Asset Management New York $3.08B AUM 21.94% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
FI
Focused Investors Los Angeles, California $3.08B AUM 12.02% 1-Year Est. Return

Tema ETFs's Q1 2025 Portfolio in Review

As of Q1 2025, Tema ETFs held 174 positions worth $335M, up 39% from $241M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Tema ETFs deployed $112M of net new capital in Q1 2025, opening 26 new positions and adding to 81 existing holdings. Its largest new stake was Bristol-Myers Squibb: 75,050 shares worth $4.58M.

By sector, the portfolio is most concentrated in Industrials at 43% of assets, down from 46% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $2.53M trimmed.

  • Tema ETFs's largest Q1 2025 buy was Bristol-Myers Squibb: 75,050 shares worth $4.58M.
  • Tema ETFs added most to Terex in Q1 2025, an estimated $6.33M increase.
  • Tema ETFs's biggest Q1 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $2.53M.
  • Tema ETFs fully exited Primoris Services in Q1 2025, selling an estimated $7.13M.
  • Tema ETFs's ten largest holdings make up 29% of its $335M portfolio in Q1 2025.
  • Tema ETFs opened 26 new positions and closed 27 in Q1 2025.
  • Tema ETFs's portfolio value rose 39% quarter-over-quarter to $335M.

Based on Tema ETFs's 13F filing for Q1 2025, filed 14 May 2025.